ARHGAP10 and breast cancer: We therefore hypothesized that there was a relationship between the expression of ARHGAP10 and chemotherapy response, and the combination of epirubicin, cyclophosphamide and docetaxel may be less effective in breast cancer patients with low expression of ARHGAP10.